Vita 34 AG (V3V) | Finanzwire

Basculer en Français

8298	Companies
114933	Keywords
55342	Articles
62466	Press releases

Home
Companies
Vita 34 AG

BRIEF

published on 04/19/2024 at 12:33, 7 months 2 days ago

Vita 34 Achieves Better Than Expected Financial Results for 2023

EBITDA Revenue Growth Financial Performance Earnings Report Vita 34 AG
PRESS RELEASE

published on 04/19/2024 at 12:28, 7 months 2 days ago

EQS-Adhoc: Vita 34 closes 2023 with significantly better results than expected based on preliminary figures
Vita 34 AG exceeds 2023 earnings expectations with EUR 5.6 million EBITDA, forecasts revenues of EUR 81-88 million and EBITDA of EUR 6.5-8.0 million for 2024

Revenues EBITDA Forecast Earnings Vita 34 AG
PRESS RELEASE

published on 01/31/2024 at 17:03, 9 months 20 days ago

EQS-Adhoc: Vita 34 publishes preliminary figures on the course of business in 2023
Vita 34 AG publishes preliminary figures on the course of business in 2023, reporting Group revenue of EUR 76.8 million and preliminary EBITDA of EUR 4.0 million, which fell short of expectations due to extraordinary charges. The company plans to invest in cell and gene therapies and CDMO following the merger with PBKM

EBITDA 2023 Vita 34 AG Preliminary Figures Cell And Gene Therapies
PRESS RELEASE

published on 11/10/2023 at 14:57, 1 year ago

EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements
PRESS RELEASE

published on 09/27/2023 at 19:21, 1 year 1 month ago

EQS-Adhoc: Vita 34 AG: A subsidiary of Vita 34, FamiCordTx, will file a lawsuit against a US licensor
PRESS RELEASE

published on 08/31/2023 at 10:30, 1 year 2 months ago

Vita 34 stabilizes business development in the second quarter and noticeably improves earnings
PRESS RELEASE

published on 05/31/2023 at 08:00, 1 year 5 months ago

Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment
PRESS RELEASE

published on 05/12/2023 at 09:10, 1 year 6 months ago

Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate
PRESS RELEASE

published on 04/30/2023 at 12:00, 1 year 6 months ago

Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
PRESS RELEASE

published on 04/25/2023 at 18:43, 1 year 6 months ago

EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year

Accesswire

Published on 11/21/2024 at 14:00, 19 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 19 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 19 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 19 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report
Published on 11/21/2024 at 13:30, 49 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:00, 19 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 1 hour 4 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 44 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 2 hours 4 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 2 hours 13 minutes ago

IVU AG publishes Quarterly Report Q3-2024

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 21 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 59 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 34 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 34 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE